No UPCODE Act Targets Medicare Advantage Overpayments

Medicare policy is not usually the place people go for drama. It is more spreadsheets than soap opera, more actuarial memo than cliffhanger. But every so often, a bill lands in Washington with a name sharp enough to cut through the jargon. The No UPCODE Act is one of those bills. Its target is Medicare Advantage overpayments, especially the kind tied to aggressive diagnosis coding that can make patients look sicker on paper than they appear in actual treatment records.

That is the central fight. Medicare Advantage plans are paid more for enrollees with more serious health conditions. In theory, that makes sense. Sicker patients usually cost more. In practice, however, the system also creates a giant neon incentive sign that says, “Please document every diagnosis, every possible complication, and maybe the kitchen sink too.” Supporters of the No UPCODE Act argue that the payment model has drifted too far from rewarding care and too close to rewarding coding. Critics say the bill risks cutting benefits people genuinely like, including dental, vision, hearing, and lower out-of-pocket costs.

The result is a classic Washington battle with a very unglamorous star: risk adjustment. Yet the stakes are huge. Medicare Advantage now covers a majority of eligible Medicare beneficiaries, so even small changes in payment policy can move billions of dollars. This is not a niche policy tiff for people who alphabetize federal registers for fun. It is a live argument about taxpayer dollars, Medicare premiums, insurer behavior, and whether the program is paying for better care or just better paperwork.

What the No UPCODE Act is trying to do

The No UPCODE Act is a bipartisan proposal built around a straightforward idea: if Medicare Advantage plans are being overpaid because of coding practices that do not reflect real clinical need, then the payment formula should stop rewarding those practices.

At its core, the legislation would push Medicare to exclude certain diagnoses from payment calculations when those diagnoses come from chart reviews or health risk assessments, rather than from ordinary care encounters tied to ongoing treatment. It would also require the use of two years of diagnostic data, not just one, to reduce the impact of one-off coding spikes. And it would direct Medicare to better account for the coding differences between Medicare Advantage and traditional Medicare when setting payment adjustments.

That may sound wonky, but the logic is pretty simple. A diagnosis that appears once during a home assessment, then never shows up again in treatment records, tests, prescriptions, or follow-up visits, should probably not function like a golden ticket to a permanently higher payment. Supporters of the bill say that is not reforming Medicare with a chainsaw. It is basic housekeeping. A very expensive housekeeping job, but housekeeping all the same.

Importantly, the No UPCODE Act is not currently law. It is better understood as part of an ongoing congressional effort to tighten Medicare Advantage payment policy after years of warnings from watchdogs, researchers, and enforcement agencies.

Why Medicare Advantage overpayments have become such a big issue

The Medicare Advantage program has grown from an alternative option into the main event. Millions of older adults choose it because it often includes extra benefits, annual out-of-pocket limits, and lower premiums than a traditional Medicare package paired with supplemental coverage. From a consumer standpoint, that can be very attractive. From a policy standpoint, the question is whether taxpayers are overpaying to support that attractiveness.

That concern has become impossible to ignore. Analysts have argued that Medicare Advantage payments are running ahead of what the same beneficiaries would cost in traditional Medicare. The concern is not merely that plans are being paid a lot. Medicare pays a lot for many things. The concern is that the payment gap may reflect gaming, not genuine illness burden.

The reason the issue keeps coming back is that risk adjustment is supposed to protect insurers from being punished for enrolling sicker people. It is not supposed to become a revenue sport. Yet that is exactly where many critics say the system has drifted. When diagnoses drive payment, and when plans have tools to gather additional diagnoses outside the normal flow of care, the temptation is obvious. If a code can boost a risk score, and a risk score can boost a payment, then somebody somewhere will eventually build a business model around finding more codes.

And that is where the policy mood has shifted. The debate is no longer about whether coding intensity exists. The debate is about how much it costs, how much of it is legitimate, and how long Congress is willing to shrug while the meter keeps running.

How “upcoding” works in plain English

Upcoding, in this context, does not always mean inventing illnesses out of thin air. Sometimes it is more subtle than that. It can mean pushing hard to capture every diagnosis that raises a risk score, even when that condition is not actively being treated, is no longer clinically relevant, or appears only in paperwork disconnected from ongoing care.

Two tools draw the most attention: chart reviews and health risk assessments. A chart review is exactly what it sounds like. A plan, or a vendor working for a plan, reviews medical records to identify diagnoses that may not have been submitted with a claim. A health risk assessment is an evaluation, often completed during an annual wellness visit or in the home, designed to identify a patient’s conditions and needs.

Neither tool is inherently bad. In fact, both can serve real clinical purposes. A well-done assessment can uncover unmet needs. A chart review can correct records. The problem begins when these tools function less like care coordination and more like diagnosis harvesting. If a condition shows up on an assessment or review, bumps up the risk score, increases the payment, and then disappears from the person’s actual care journey, critics say Medicare has every right to ask what exactly it just paid for.

That concern is why the No UPCODE Act focuses so heavily on diagnoses captured outside the ordinary arc of treatment. Think of it as Congress asking one very reasonable question: should a diagnosis count the same when it appears in a billing-sensitive assessment as when it appears in the course of ongoing medical care? For supporters of the bill, the answer is a firm “absolutely not.”

The evidence behind the push for reform

The reform campaign is not based on vibes, rumors, or somebody’s cousin who once had a bad experience with paperwork. It is driven by a growing pile of research and enforcement actions.

Policy analysts have estimated that Medicare Advantage payments in 2025 exceed what traditional Medicare would have spent for similar beneficiaries by tens of billions of dollars. A large share of that gap has been linked to coding intensity and favorable selection. In other words, part of the payment difference appears to come from how diagnoses are documented and from who enrolls, not just from care management magic.

Researchers and watchdogs have also zeroed in on chart reviews and health risk assessments. These practices have been associated with substantial additional payments, especially when diagnoses are added without clear evidence of related follow-up services. Federal oversight reports have warned that some diagnoses documented only on in-home assessments or linked chart reviews raise questions about whether the condition was valid, whether care was coordinated, or whether the diagnosis mainly existed to increase payment.

There is also the enforcement angle, which has turned up the heat. The Justice Department has pursued Medicare Advantage cases involving allegedly inaccurate diagnosis submissions and failures to delete unsupported codes. Recent settlements involving major insurers have reinforced the message that risk adjustment is not a paperwork sandbox where anything goes. When federal prosecutors start looking at diagnosis inflation, Washington stops treating the matter like an academic seminar and starts treating it like a budget and compliance problem.

Even outside direct payment policy, scrutiny of Medicare Advantage has broadened. Questions about prior authorization, denials, and access to medically necessary care have added to the sense that the program deserves tougher oversight overall. That does not prove every overpayment claim. But it does create a climate in which Congress is more willing to listen when someone says the payment system may be too easy to manipulate.

What supporters say the bill would fix

Supporters of the No UPCODE Act argue that the bill would not dismantle Medicare Advantage. It would simply reduce payments that are inflated by coding practices not seen in traditional Medicare. Their pitch is that the reform is about accuracy, not punishment.

They also say the savings matter beyond the federal ledger. When Medicare pays more than necessary to private plans, those costs do not float into the sky and disappear like a polite balloon. They put pressure on the Medicare trust funds and can spill into premiums paid by beneficiaries across the program. One congressional report in 2026 even argued that alleged Medicare Advantage overpayments pushed Part B premiums higher for seniors. That is the kind of finding that turns an abstract coding debate into kitchen-table politics very quickly.

Supporters further argue that extra benefits in Medicare Advantage should not depend on inflated payments. If a plan can provide dental, vision, or lower cost sharing because it is genuinely efficient, great. If it can only provide those benefits because the government is overpaying based on diagnoses that never translate into care, that is a different story. The bill’s backers want those two stories separated.

What critics worry about

Critics, including industry voices, do not deny that coding policy matters. Their argument is that blunt payment cuts could ripple through benefits, plan choices, and premiums for the millions of people already enrolled in Medicare Advantage. They say diagnoses captured through assessments can reveal real health needs that might otherwise go undocumented, especially for older adults with complex or poorly coordinated care.

There is also a practical concern. If Congress changes the rules too aggressively or too quickly, plans may respond by trimming supplemental benefits, narrowing networks, or becoming more selective about the markets they serve. Nobody wants Medicare reform to become a surprise demolition derby.

That said, recent analyses suggest the impact of payment changes is not always as dramatic as industry warnings imply. When payment pressure rises, plans do not automatically slash beloved extras on day one and send seniors into the streets clutching abandoned gym memberships. Some evidence suggests insurers often have room to absorb at least part of the hit through lower margins or administrative changes. That is why the real policy question is not whether reform has tradeoffs. It is whether the current level of payment inflation is worth them.

What happens next

The No UPCODE Act sits inside a bigger reform conversation that is far from over. Congress can act directly, CMS can keep adjusting models and audit practices, and enforcement agencies can keep pressuring plans through investigations and settlements. Reform may ultimately arrive through one giant bill, several smaller policy changes, or a steady tightening of rules that makes the system less rewarding for aggressive coding over time.

Either way, the direction of travel is clear. Medicare Advantage is now too large, too expensive, and too central to Medicare’s future for lawmakers to ignore questions about overpayments. The era when critics could be waved off as anti-private-plan scolds is fading fast. The debate has moved into a more mature phase, where policymakers are asking how to preserve what beneficiaries like without continuing to overpay for what taxpayers should not have to subsidize.

The No UPCODE Act may not be law today, but it captures the policy mood of the moment perfectly. Medicare Advantage can stay popular. It just may not get to stay sloppy.

Real-world experiences behind the debate

The policy arguments around the No UPCODE Act can sound abstract, but the lived experience behind them is anything but abstract. Start with the beneficiary who agrees to a home assessment because it sounds helpful, friendly, and free. A nurse or clinician asks thoughtful questions, checks medications, notes chronic issues, and flags concerns. From the patient’s perspective, it may feel like a wellness visit with better parking. What the patient often does not see is the second life of that visit in the payment system. A diagnosis captured in that setting can increase what Medicare pays the plan, even if the patient never gets follow-up care tied to that diagnosis. For many seniors, the strange part is not the visit itself. It is realizing that a quiet conversation in the living room can echo loudly in a federal reimbursement formula.

Then there is the physician experience. Doctors and office staff are already drowning in documentation, and Medicare Advantage can add another layer of queries, prompts, and “please clarify this condition” requests. Some of those requests are clinically valid. Some feel like the medical equivalent of being asked whether a grocery receipt might also qualify as a screenplay. Providers can feel caught between doing careful documentation and becoming unpaid extras in a coding optimization operation. The frustration is not always ideological. It is practical. Clinicians want to treat patients, not spend the afternoon debating whether an old diagnosis should be refreshed for payment purposes.

Compliance professionals inside health plans have their own version of the story. In many organizations, they are the people in the meeting quietly asking whether a diagnosis is truly supported, whether a deleted code should be reported back, or whether a chart review is being used to improve accuracy or just chase revenue. These teams know that “everybody does it” is not a legal defense, and recent federal settlements have only intensified that pressure. For them, the No UPCODE Act represents not just a payment change but also a governance test. It would make it harder to blur the line between valid risk adjustment and opportunistic documentation.

Taxpayers and traditional Medicare beneficiaries experience the issue more indirectly, but no less meaningfully. They see it through higher program costs, through pressure on Medicare financing, and potentially through higher premiums. That can feel deeply unfair. A beneficiary in traditional Medicare may wonder why private plans get generous extra benefits while the public program footing part of the bill does not offer the same goodies. That is the emotional fuel behind overpayment reform. It is not just about whether plans code more intensely. It is about whether the public is being asked to finance advantages that rest partly on payment distortions.

Finally, there is the broader public experience: confusion. Most people hear “Medicare Advantage overpayments” and assume someone must have found bags of cash hidden behind a copier. The reality is messier. The money moves through formulas, diagnoses, benchmarks, risk scores, and audits. That complexity is exactly why the issue has lasted so long. The No UPCODE Act speaks to a growing impatience with that complexity. People do not need to understand every coding manual to grasp the principle. If the system pays more because of diagnoses that exist mainly on paper, the system needs fixing. That instinct is not partisan, and it is not academic. It is common sense in a blazer.

Conclusion

The No UPCODE Act matters because it takes one of Medicare’s most technical problems and gives it a plain-English mission: stop rewarding diagnosis inflation in Medicare Advantage. The bill does not solve every concern surrounding the program, and it does not erase the fact that many enrollees genuinely value the benefits Medicare Advantage offers. But it does force a necessary question into the open. Should taxpayer-funded payments reflect actual clinical need, or should they keep bending to documentation tactics that can outpace care itself?

That question is not going away. As Medicare Advantage keeps growing, the pressure to make its payment system more accurate will only intensify. The No UPCODE Act may or may not be the final form of reform, but it has already done something important: it has turned overpayments from a background policy murmur into a headline issue. In Washington terms, that is the moment when a technical problem stops being invisible and starts becoming actionable.